The clinical characteristics including age, gender, tumor location, tumor size, tumor differentiation, AJCC disease stage, KRAS/NRAS/BRAF mutation status, non-quantitative FOBT, serum CEA and CA19-9 were matched between oCRC group and yCRC group. This evidence concerns the gene KRAS and neoplasm.